Covered recipient · General Payments record
LON D LYNN
Allopathic & Osteopathic Physicians Family Medicine
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2022 · Entire year
$317.77
13 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2022 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $317.77 | 13 |
By paying entity
PY2022 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Xeris Pharmaceuticals, Inc. | $111.86 | 1 |
| Novo Nordisk Inc | $79.40 | 4 |
| Janssen Pharmaceuticals, Inc | $19.11 | 1 |
| Amneal Pharmaceuticals LLC | $16.88 | 1 |
| Amgen Inc. | $16.67 | 1 |
| Currax Pharmaceuticals LLC | $16.41 | 1 |
| Mylan Specialty L.P. | $15.59 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $14.51 | 1 |
| Merck Sharp & Dohme LLC | $14.02 | 1 |
| SANOFI-AVENTIS U.S. LLC | $13.32 | 1 |
Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
LON D LYNN
NPI 1497898282 · CMS profile ID 204601
Allopathic & Osteopathic Physicians / Family Medicine
TAMPA, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1497898282?year=2022&recipient=provider#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- LON D LYNN, NPI 1497898282, CMS profile ID 204601. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1497898282?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- APA 7
- IndustryPayments. (2026). LON D LYNN, NPI 1497898282, CMS profile ID 204601. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1497898282?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
- Bluebook
- LON D LYNN, NPI 1497898282, CMS profile ID 204601, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1497898282?year=2022&recipient=provider#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2022
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30
13 matching records · $317.77 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 1–13 of 13.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Xeris Pharmaceuticals, Inc. | $111.86 | 12/01/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 946483565 | CMS |
| Novo Nordisk Inc | $17.26 | 07/19/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 898731519 | CMS |
| Amgen Inc. | $16.67 | 03/03/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 939271275 | CMS |
| Novo Nordisk Inc | $24.78 | 03/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 898905593 | CMS |
| Mylan Specialty L.P. | $15.59 | 02/25/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 963896071 | CMS |
| Amneal Pharmaceuticals LLC | $16.88 | 02/24/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 956585949 | CMS |
| Novo Nordisk Inc | $17.45 | 02/23/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 898855126 | CMS |
| Novo Nordisk Inc | $19.91 | 02/17/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 898629311 | CMS |
| Currax Pharmaceuticals LLC | $16.41 | 02/16/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 925770539 | CMS |
| Merck Sharp & Dohme LLC | $14.02 | 02/10/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 944775579 | CMS |
| Janssen Pharmaceuticals, Inc | $19.11 | 02/09/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 886017719 | CMS |
| Bayer HealthCare Pharmaceuticals Inc. | $14.51 | 02/02/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 930058201 | CMS |
| SANOFI-AVENTIS U.S. LLC | $13.32 | 01/26/2022 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 938751865 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024
Source files and profile matching
- Generated from
- OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $2,774,310.43 | 131 |
| PY2024 | Recipient | $1,401.65 | 10 |
| PY2024 | Principal investigator | $1,886,016.65 | 154 |
| PY2023 | Recipient | $1,734.07 | 2 |
| PY2023 | Principal investigator | $1,613,093.87 | 174 |
| PY2022 | Recipient | $7,938.00 | 2 |
| PY2022 | Principal investigator | $1,203,947.96 | 117 |
| PY2021 | Recipient | $1,793.52 | 3 |
| PY2021 | Principal investigator | $874,519.06 | 78 |
| PY2020 | Principal investigator | $706,623.45 | 80 |
| PY2019 | Recipient | $1,208.55 | 9 |
| PY2019 | Principal investigator | $596,855.42 | 115 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
176 records in PY2023
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $18,988.94 | 12/31/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) | No dispute reported | 06/30/2026 | 991127101 |
| Principal investigator 1 | AstraZeneca UK Limited | $1,002.56 | 12/31/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Phase 2 Multinational Randomized Double blind Parallel group 16 week Placebo controlled Study with a 36 week Extension to Investigate the Use of Benralizumab for Patients with Moderate to Severe Atopic Dermatitis Despite Treatment with Topical Medications | No dispute reported | 06/30/2026 | 991134581 |
| Principal investigator 1 | Averitas Pharma Inc. | $1,913.40 | 12/19/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763677 |
| Principal investigator 1 | Eli Lilly and Company | $14,000.00 | 12/18/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1038078383 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,925.00 | 12/18/2023 | Non-covered Recipient Entity Clinical Research Of West Florida | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1036001985 |
| Principal investigator 1 | Biogen, Inc. | $23,304.45 | 12/14/2023 | Non-covered Recipient Entity Clinical Research Of West Florida | A Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS) (CYPRESS) | No dispute reported | 06/30/2026 | 1012178101 |
| Principal investigator 1 | Averitas Pharma Inc. | $862.20 | 12/08/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763675 |
| Principal investigator 1 | Averitas Pharma Inc. | $2,059.20 | 11/28/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763673 |
| Principal investigator 1 | Averitas Pharma Inc. | $5,582.70 | 11/21/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763671 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,450.00 | 11/20/2023 | Non-covered Recipient Entity Clinical Research Of West Florida | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1036001966 |
| Principal investigator 1 | Averitas Pharma Inc. | $6,779.70 | 11/17/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763669 |
| Principal investigator 1 | ABBVIE INC. | $2,500.00 | 11/08/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 998407309 |
| Principal investigator 1 | ABBVIE INC. | $5,030.80 | 11/07/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 998406479 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $2.94 | 11/07/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059683209 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $4.90 | 11/07/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059684197 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $9.31 | 11/07/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059684969 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $7.84 | 11/07/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059685683 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $7.35 | 11/07/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059686605 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $6.86 | 11/07/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059686981 |
| Principal investigator 1 | Mylan Specialty L.P. | $7,479.25 | 11/03/2023 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) | No dispute reported | 06/30/2026 | 1038208571 |
| Principal investigator 1 | Averitas Pharma Inc. | $1,500.00 | 10/25/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763659 |
| Principal investigator 1 | Averitas Pharma Inc. | $2,000.00 | 10/25/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763661 |
| Principal investigator 1 | Averitas Pharma Inc. | $3,663.00 | 10/25/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763663 |
| Principal investigator 1 | Averitas Pharma Inc. | $4,500.00 | 10/25/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763665 |
| Principal investigator 1 | Averitas Pharma Inc. | $1,500.00 | 10/25/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763667 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $18,950.00 | 10/23/2023 | Non-covered Recipient Entity Clinical Research Of West Florida | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1036001927 |
| Principal investigator 1 | ABBVIE INC. | $280.00 | 10/17/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) | No dispute reported | 06/30/2026 | 998404331 |
| Principal investigator 1 | Averitas Pharma Inc. | $1,603.80 | 10/17/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763657 |
| Principal investigator 1 | ABBVIE INC. | $1,542.45 | 10/12/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 998403897 |
| Principal investigator 1 | Eli Lilly and Company | $3,155.50 | 10/05/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 3 RANDOMIZED OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH ORAL SEMAGLUTIDE IN ADULT PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH METFORMIN (ACHIEVE-3) | No dispute reported | 06/30/2026 | 1038083041 |
| Principal investigator 1 | ABBVIE INC. | $3,095.75 | 10/04/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) | No dispute reported | 06/30/2026 | 998401759 |
| Principal investigator 1 | Averitas Pharma Inc. | $1,913.40 | 10/03/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763655 |
| Principal investigator 1 | UCB SA | $756.00 | 10/02/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATMENT IN STUDY PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | No dispute reported | 06/30/2026 | 1059101303 |
| Principal investigator 1 | Averitas Pharma Inc. | $2,302.20 | 09/21/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763653 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,300.00 | 09/18/2023 | Non-covered Recipient Entity Clinical Research Of West Florida | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1036001917 |
| Principal investigator 1 | ABBVIE INC. | $2,280.25 | 09/13/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 998399365 |
| Principal investigator 1 | ABBVIE INC. | $1,822.50 | 09/13/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) | No dispute reported | 06/30/2026 | 998399367 |
| Principal investigator 1 | Averitas Pharma Inc. | $2,642.40 | 09/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763651 |
| Principal investigator 1 | Averitas Pharma Inc. | $5,904.90 | 09/01/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763649 |
| Principal investigator 1 | Mylan Specialty L.P. | $11,155.25 | 09/01/2023 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) | No dispute reported | 06/30/2026 | 1038208565 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $327.90 | 08/28/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN | No dispute reported | 06/30/2026 | 1006258741 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $550.00 | 08/28/2023 | Non-covered Recipient Entity Clinical Research Of West Florida | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1036001905 |
| Principal investigator 1 | ABBVIE INC. | $1,105.00 | 08/24/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) | No dispute reported | 06/30/2026 | 998396583 |
| Principal investigator 1 | AstraZeneca UK Limited | $5,685.68 | 08/23/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Phase 2b Multinational Randomised Double-blind Parallelgroup 24-week Placebo-controlled Study with 28-week Extension to Investigate the Use of Benralizumab in Patients with Moderate to Severe Chronic Spontaneous Urticaria | No dispute reported | 06/30/2026 | 991137135 |
| Principal investigator 1 | Averitas Pharma Inc. | $3,353.40 | 08/18/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763647 |
| Principal investigator 1 | ABBVIE INC. | $5,872.50 | 08/15/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) | No dispute reported | 06/30/2026 | 998395457 |
| Principal investigator 1 | ABBVIE INC. | $323.25 | 08/10/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 998394687 |
| Principal investigator 1 | Averitas Pharma Inc. | $12,276.00 | 08/10/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763645 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $122,482.89 | 07/26/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1017200863 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,100.00 | 07/24/2023 | Non-covered Recipient Entity Clinical Research Of West Florida | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1036001885 |
| Principal investigator 1 | ABBVIE INC. | $4,844.80 | 07/20/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) | No dispute reported | 06/30/2026 | 998391971 |
| Principal investigator 1 | Averitas Pharma Inc. | $3,663.00 | 07/18/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763643 |
| Principal investigator 1 | ABBVIE INC. | $6,311.05 | 07/13/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 998391335 |
| Principal investigator 3 | UCB SA | $26,822.00 | 07/12/2023 | Non-covered Recipient Entity Clinical Research Of West Florida | A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF DAPIROLIZUMAB PEGOL TREATMENT IN STUDY PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS | No dispute reported | 06/30/2026 | 1059101177 |
| Principal investigator 1 | ABBVIE INC. | $2,497.50 | 07/11/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) | No dispute reported | 06/30/2026 | 998390097 |
| Principal investigator 1 | ABBVIE INC. | $952.00 | 07/11/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) | No dispute reported | 06/30/2026 | 998390287 |
| Principal investigator 1 | ABBVIE INC. | $1,542.45 | 07/11/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 998390289 |
| Principal investigator 1 | Averitas Pharma Inc. | $1,603.80 | 07/11/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763641 |
| Principal investigator 1 | Eli Lilly and Company | $2,686.26 | 07/11/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | No dispute reported | 06/30/2026 | 1038101323 |
| Principal investigator 1 | Averitas Pharma Inc. | $3,906.00 | 07/04/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763637 |
| Principal investigator 1 | Averitas Pharma Inc. | $1,749.60 | 07/04/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763639 |
| Principal investigator 1 | ABBVIE INC. | $1,903.95 | 06/21/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 998387675 |
| Principal investigator 1 | Averitas Pharma Inc. | $4,246.20 | 06/20/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763635 |
| Principal investigator 1 | Averitas Pharma Inc. | $1,500.00 | 06/13/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763629 |
| Principal investigator 1 | Averitas Pharma Inc. | $2,250.00 | 06/13/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763631 |
| Principal investigator 1 | Averitas Pharma Inc. | $2,387.70 | 06/13/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763633 |
| Principal investigator 1 | ABBVIE INC. | $10,249.03 | 06/08/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) | No dispute reported | 06/30/2026 | 998386007 |
| Principal investigator 1 | Averitas Pharma Inc. | $1,603.80 | 06/08/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763627 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $314.28 | 06/02/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059680923 |
| Principal investigator 1 | Mylan Specialty L.P. | $19,557.50 | 06/01/2023 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) | No dispute reported | 06/30/2026 | 1038208577 |
| Principal investigator 1 | Averitas Pharma Inc. | $1,913.40 | 05/30/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763625 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $550.00 | 05/25/2023 | Non-covered Recipient Entity Clinical Research Of West Florida | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1036001833 |
| Principal investigator 1 | ABBVIE INC. | $2,550.00 | 05/24/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) | No dispute reported | 06/30/2026 | 998384321 |
| Principal investigator 1 | Averitas Pharma Inc. | $1,603.80 | 05/24/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763623 |
| Principal investigator 1 | Averitas Pharma Inc. | $135.00 | 05/19/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763619 |
| Principal investigator 1 | Averitas Pharma Inc. | $2,652.75 | 05/19/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763621 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,352.50 | 05/18/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN | No dispute reported | 06/30/2026 | 1006258735 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $1,500.00 | 05/18/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A 52-WEEK, PHASE 3, MULTICENTRE, RANDOMISED, DOUBLE BLIND, EFFICACY AN | No dispute reported | 06/30/2026 | 1006258747 |
| Principal investigator 1 | ABBVIE INC. | $5,569.25 | 05/16/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 998383433 |
| Principal investigator 1 | Averitas Pharma Inc. | $3,353.40 | 05/16/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763617 |
| Principal investigator 1 | ABBVIE INC. | $9,429.09 | 05/11/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) | No dispute reported | 06/30/2026 | 998382191 |
| Principal investigator 1 | Mylan Specialty L.P. | $384.25 | 05/10/2023 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) | No dispute reported | 06/30/2026 | 1038208625 |
| Principal investigator 1 | Averitas Pharma Inc. | $1,749.60 | 05/09/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763615 |
| Principal investigator 1 | Averitas Pharma Inc. | $3,663.00 | 05/03/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763613 |
| Principal investigator 1 | Eli Lilly and Company | $45,450.00 | 05/02/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 3 PARALLEL-DESIGN OPEN-LABEL RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 ADMINISTERED WEEKLY USING A FIXED DOSE ESCALATION COMPARED TO INSULIN GLARGINE IN INSULIN-NAIVE ADULTS WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1038085127 |
| Principal investigator 1 | Averitas Pharma Inc. | $1,603.80 | 04/26/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763611 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $9,700.00 | 04/24/2023 | Non-covered Recipient Entity Clinical Research Of West Florida | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1036001811 |
| Principal investigator 1 | Averitas Pharma Inc. | $2,156.40 | 04/18/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763609 |
| Principal investigator 1 | ABBVIE INC. | $1,542.45 | 04/13/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 998378161 |
| Principal investigator 1 | ABBVIE INC. | $8,033.86 | 04/13/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) | No dispute reported | 06/30/2026 | 998378203 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $692.90 | 04/10/2023 | Non-covered Recipient Entity Clinical Research Of West Florida | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1036001803 |
| Principal investigator 1 | ABBVIE INC. | $1,532.50 | 04/05/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 998376945 |
| Principal investigator 1 | Averitas Pharma Inc. | $7,928.10 | 04/04/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763605 |
| Principal investigator 1 | Averitas Pharma Inc. | $309.60 | 04/04/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763607 |
| Principal investigator 1 | Eli Lilly and Company | $225,500.00 | 04/04/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1038076121 |
| Principal investigator 1 | Mylan Specialty L.P. | $1,901.47 | 03/31/2023 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) | No dispute reported | 06/30/2026 | 1038208583 |
| Principal investigator 1 | Averitas Pharma Inc. | $2,059.20 | 03/29/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763603 |
| Principal investigator 1 | Averitas Pharma Inc. | $1,000.00 | 03/21/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763597 |
| Principal investigator 1 | Averitas Pharma Inc. | $1,603.80 | 03/21/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763599 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $10,825.00 | 03/20/2023 | Non-covered Recipient Entity Clinical Research Of West Florida | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1036001775 |
| Principal investigator 1 | ABBVIE INC. | $323.25 | 03/16/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 998374441 |
| Principal investigator 1 | ABBVIE INC. | $1,778.15 | 03/16/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 998374687 |
| Principal investigator 1 | ABBVIE INC. | $9,007.21 | 03/16/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) | No dispute reported | 06/30/2026 | 998374689 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,235.00 | 03/13/2023 | Non-covered Recipient Entity Clinical Research Of West Florida | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1036001765 |
| Principal investigator 1 | Averitas Pharma Inc. | $4,451.75 | 03/08/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763585 |
| Principal investigator 1 | Averitas Pharma Inc. | $1,215.00 | 03/08/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763587 |
| Principal investigator 1 | Averitas Pharma Inc. | $4,725.00 | 03/08/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763589 |
| Principal investigator 1 | Averitas Pharma Inc. | $405.00 | 03/08/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763595 |
| Principal investigator 1 | Mylan Specialty L.P. | $11,960.02 | 03/08/2023 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) | No dispute reported | 06/30/2026 | 1038208643 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,000.00 | 03/06/2023 | Non-covered Recipient Entity Clinical Research Of West Florida | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1036001727 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $1,500.00 | 03/06/2023 | Non-covered Recipient Entity Clinical Research Of West Florida | Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/ REGN3500/ Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1036001745 |
| Principal investigator 1 | Averitas Pharma Inc. | $309.60 | 02/28/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763583 |
| Principal investigator 1 | Eli Lilly and Company | $1,323.72 | 02/23/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A MASTER PROTOCOL FOR A RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | No dispute reported | 06/30/2026 | 1038085117 |
| Principal investigator 1 | Averitas Pharma Inc. | $2,500.00 | 02/22/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763577 |
| Principal investigator 1 | Averitas Pharma Inc. | $2,250.00 | 02/22/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763579 |
| Principal investigator 1 | Averitas Pharma Inc. | $1,913.40 | 02/22/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763581 |
| Principal investigator 1 | Averitas Pharma Inc. | $2,156.40 | 02/16/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763575 |
| Principal investigator 1 | UCB SA | $16,051.76 | 02/16/2023 | Non-covered Recipient Entity Clinical Research Of West Florida | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | No dispute reported | 06/30/2026 | 1059100381 |
| Principal investigator 1 | Mylan Specialty L.P. | $15,089.74 | 02/15/2023 | Non-covered Recipient Entity Clinical Research of West Florida, Inc. | A Phase 4, Randomized, Double-Blind, Double-Dummy, Parallel Group Study Comparing Improvements in Lung Function in Adults With Severe to Very Severe Chronic Obstructive Pulmonary Disease and Suboptimal Inspiratory Flow Rate Following Once-Daily Treatment Over 12 Weeks With Either Revefenacin Inhalation Solution Delivered via Standard Jet Nebulizer or Tiotropium Delivered via a Dry Powder Inhaler (Spiriva HandiHaler) | No dispute reported | 06/30/2026 | 1038208607 |
| Principal investigator 1 | Eli Lilly and Company | $40,000.00 | 02/14/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A MASTER PROTOCOL FOR A RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | No dispute reported | 06/30/2026 | 1038082065 |
| Principal investigator 1 | ABBVIE INC. | $6,455.03 | 02/09/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) | No dispute reported | 06/30/2026 | 998369331 |
| Principal investigator 1 | ABBVIE INC. | $1,293.00 | 02/09/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 998369333 |
| Principal investigator 1 | Averitas Pharma Inc. | $1,749.60 | 02/09/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763571 |
| Principal investigator 1 | Averitas Pharma Inc. | $5,250.00 | 02/09/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763573 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $40,423.26 | 02/08/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Phase IIa Randomised, Double Blind, Placebo Controlled, Parallel Arm, Multi-Centre Study to Evaluate the Efficacy and Safety of AZD4831, for 12-24 Weeks, in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 991131195 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $164.80 | 02/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059678667 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $144.20 | 02/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059678783 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $154.50 | 02/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059678861 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $103.00 | 02/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059678985 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $195.70 | 02/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059679007 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $61.80 | 02/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059679097 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $6.00 | 02/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059679213 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $4.80 | 02/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059679335 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $4.20 | 02/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059679465 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $4.50 | 02/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059679549 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $3.00 | 02/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059679701 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $5.70 | 02/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059679725 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $3.00 | 02/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059679831 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $1.80 | 02/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059679849 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $55.96 | 02/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059679963 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $27.98 | 02/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059680147 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $38.80 | 02/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059680241 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $6.30 | 02/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059680443 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $5.40 | 02/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059680531 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $6.30 | 02/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059680591 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $3.60 | 02/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059680687 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $8.10 | 02/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059680711 |
| Principal investigator 1 | JAZZ PHARMACEUTICALS INC. | $5.40 | 02/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 4 MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY OF SAFETY, TOLERABILITY, EFFECTIVENESS AND TREATMENT OPTIMIZATION IN PARTICIPANTS SWITCHING FROM XYREM TO XYWAV FOR THE TREATMENT OF NARCOLEPSY | No dispute reported | 06/30/2026 | 1059680791 |
| Principal investigator 1 | ABBVIE INC. | $5,000.00 | 02/02/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) | No dispute reported | 06/30/2026 | 998368505 |
| Principal investigator 1 | Averitas Pharma Inc. | $5,995.80 | 02/02/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763569 |
| Principal investigator 1 | AstraZeneca UK Limited | $6,052.57 | 02/01/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Phase 2 Multinational Randomized Double blind Parallel group 16 week Placebo controlled Study with a 36 week Extension to Investigate the Use of Benralizumab for Patients with Moderate to Severe Atopic Dermatitis Despite Treatment with Topical Medications | No dispute reported | 06/30/2026 | 991137587 |
| Recipient | Eli Lilly and Company | $298.02 | 01/31/2023 | Covered Recipient Physician | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) | No dispute reported | 06/30/2026 | 1038052267 |
| Principal investigator 1 | Eli Lilly and Company | $2,546.87 | 01/26/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL-GROUP TWO-ARM PHASE 2 CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3361237 AS A TREATMENT FOR ADULTS WITH AT LEAST MODERATELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | No dispute reported | 06/30/2026 | 1038079199 |
| Principal investigator 1 | Eli Lilly and Company | $4,876.45 | 01/26/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 3 PARALLEL-DESIGN OPEN-LABEL RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 ADMINISTERED WEEKLY USING A FIXED DOSE ESCALATION COMPARED TO INSULIN GLARGINE IN INSULIN-NAIVE ADULTS WITH TYPE 2 DIABETES | No dispute reported | 06/30/2026 | 1038082933 |
| Principal investigator 1 | Eli Lilly and Company | $153.14 | 01/26/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) | No dispute reported | 06/30/2026 | 1038083011 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $15,544.00 | 01/26/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1017209911 |
| Principal investigator 1 | Averitas Pharma Inc. | $4,446.90 | 01/25/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763567 |
| Principal investigator 1 | Averitas Pharma Inc. | $5,103.00 | 01/20/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763565 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $328,171.76 | 01/18/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Randomized, Double-Blind, 12-Week (with an Extension to 52 Weeks in a subset of Participants), Multi-Center Study to Assess the Safety of Budesonide, Glycopyrronium, and Formoterol Fumarate (BGF) | No dispute reported | 06/30/2026 | 991131295 |
| Principal investigator 1 | ABBVIE INC. | $3,422.90 | 01/12/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 998365585 |
| Principal investigator 1 | ABBVIE INC. | $11,200.29 | 01/12/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA) | No dispute reported | 06/30/2026 | 998365609 |
| Principal investigator 1 | Averitas Pharma Inc. | $965.00 | 01/12/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763559 |
| Principal investigator 1 | Averitas Pharma Inc. | $338.00 | 01/12/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763561 |
| Principal investigator 1 | Averitas Pharma Inc. | $135.00 | 01/12/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763563 |
| Principal investigator 1 | Averitas Pharma Inc. | $862.20 | 01/10/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763557 |
| Recipient | Eli Lilly and Company | $1,436.05 | 01/10/2023 | Covered Recipient Physician | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | No dispute reported | 06/30/2026 | 1038053677 |
| Principal investigator 1 | Eli Lilly and Company | $26,994.00 | 01/10/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY VERSUS PLACEBO AFTER AN INTENSIVE LIFESTYLE PROGRAM IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES: A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED TRIAL (SURMOUNT-3) | No dispute reported | 06/30/2026 | 1038082921 |
| Principal investigator 1 | Eli Lilly and Company | $4,195.22 | 01/10/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A PHASE 3 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1038083031 |
| Principal investigator 1 | ABBVIE INC. | $9,086.33 | 01/09/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate | No dispute reported | 06/30/2026 | 998364475 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $837.00 | 01/09/2023 | Non-covered Recipient Entity Clinical Research Of West Florida - Tampa | Phase 2 CD (Primary represents Induction) - A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Crohns Disease | No dispute reported | 06/30/2026 | 1027485789 |
| Principal investigator 1 | Averitas Pharma Inc. | $309.60 | 01/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763553 |
| Principal investigator 1 | Averitas Pharma Inc. | $4,720.50 | 01/06/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | AN INTERVENTIONAL PHASE III DOUBLEBLIND RANDOMIZED CONTROLLED PARALLELGROUP MULTISITE CLINICAL TRIAL EVALUATING THE EFFICACY AND SAFETY OF QUTENZA IN SUBJECTS WITH POSTSURGICAL NEUROPATHIC PAIN | No dispute reported | 06/30/2026 | 1058763555 |
| Principal investigator 1 | ABBVIE INC. | $5,759.00 | 01/04/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | A Study to Evaluate Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Measure Up 2) | No dispute reported | 06/30/2026 | 998363643 |
| Principal investigator 1 | Eli Lilly and Company | $32,075.00 | 01/03/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A MULTICENTER RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL-GROUP TWO-ARM PHASE 2 CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3361237 AS A TREATMENT FOR ADULTS WITH AT LEAST MODERATELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | No dispute reported | 06/30/2026 | 1038079525 |
| Principal investigator 1 | Eli Lilly and Company | $39,522.00 | 01/03/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA INC | A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | No dispute reported | 06/30/2026 | 1038082087 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $122,703.15 | 01/01/2023 | Non-covered Recipient Entity CLINICAL RESEARCH OF WEST FLORIDA | An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis | No dispute reported | 06/30/2026 | 1017202429 |